We have built our business around the concept of putting known, trusted and effective molecules into innovative delivery mechanisms so that patients can benefit from improved effectiveness through reduced or improved dosing methods. This approach has led to an impressive list of pioneering ‘firsts’, including the world’s first prolonged release morphine tablets, the first 7-day analgesic patch and the first opioid agonist/antagonist combination.

Our largest area of expertise lies in analgesics, but we also have a rapidly expanding oncology portfolio and a very promising respiratory franchise. We have a healthy product pipeline with a number of analgesic, oncology and respiratory products at various stages of clinical development and scheduled for submission to the regulatory authorities in the near future.